A new AI-powered tool can detect cognitive impairment early, helping to reduce the risk of Alzheimer's and dementia.

Laromestrocel (Lomecel-B™) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disease ...

A person's 'bioenergetic age' -- or how youthfully their cells generate energy -- might be a key indicator of whether they're at risk of developing Alzheimer's disease, new research shows. The study ...

Scientists have discovered that a modified form of a natural compound found in rosemary and sage may hold potential for ...

Exscientia has advanced a drug candidate for Alzheimer's disease into human testing ... compulsive disorder billed as the first AI-designed drug to enter the clinic. Exscientia says it is the ...

A residential fire broke out in a six-storey apartment building in Lachine late Wednesday night, March 13, prompting a rapid response from the Montreal Fire Department. The incident required the ...

Detailed price information for Alpha Cognition Inc (ACOG-Q) from The Globe and Mail including charting and trades.

DiADeM is a tool to support GPs in diagnosing dementia for people living with advanced dementia in a care home setting. It has been developed by the Yorkshire and Humber Dementia Strategic Clinical ...

For me, that reality came when my grandaunt was diagnosed with Alzheimer’s and Parkinson’s disease and became one of those ...

It is specifically designed to be easy to pick up and deliver to large groups ... demonstrate an understanding of and proficiency in essential employability skills, Alzheimer's Society has developed ...

Mice with a form of Alzheimer's were then given diAcCA or a placebo three times a week for three months. The researchers looked at the effects on brain tissue and how well the mice did on exercises ...

These individuals may benefit more from early lifestyle interventions designed to decrease their bioenergetic age and potentially delay or prevent the onset of Alzheimer’s. Moving forward, Dr.